Fabienne Baffert

2.7k citations

19 papers · 1.5k indexed · 1 hit paper · h-index 13

Impact in

Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Genetics 7
- Myeloproliferative Neoplasms: Diagnosis and Treatment 6
Internal Medicine 2

Co-authors: Donald M. McDonald Gavin Thurston Dana D. Hu‐Lowe Tom Le George D. Yancopoulos Peter Bałuk Tetsuichiro Inai David R. Shalinsky
Journals: Blood (3 papers)Journal of Clinical Oncology (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Circulation Research (2 papers)American Journal of Physiology-Heart and Circulatory Physiology (2 papers)
Partner nations: Switzerland United States Spain

In The Last Decade

Fabienne Baffert

19 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts 2004 · 589 citations

Peers

Countries citing papers authored by Fabienne Baffert

Since Specialization

Citations

This map shows the geographic impact of Fabienne Baffert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabienne Baffert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabienne Baffert more than expected).

Fields of papers citing papers by Fabienne Baffert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabienne Baffert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabienne Baffert. The network helps show where Fabienne Baffert may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Fabienne Baffert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fabienne Baffert Line = papers co-authored together Fabienne Baffert links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Developing generic templates to shape the future for conducting integrated research platform trials Trials ·Madhavi Gidh‐Jain, Tom Parke, Franz König, F.C. Croxton, Peter Mesenbrink, Fabienne Baffert, ESRA BETÜL AKKOÇ	2024	5
2	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor Investigational New Drugs ·James J. Harding, Todd M. Bauer, Daniel Shao-Weng Tan, Philippe L. Bédard, Jordi Rodón, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, С.С. Мочалов, Claire Fabre, Dejan Juric	2018	7
3	Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs) Blood ·Loretta S. Li, Shuo-Chieh Wu, Nadja Kopp, Joan Montero, Jeremy Ryan, Bjoern Chapuy, Uglješa Georgijević, Jacob V. Layer, Oliver Weigert, Amanda L. Christie, Alexandra Christodoulou, Huiyun Liu, Akinori Yoda, Francesco Hofmann, Fabienne Baffert, Eric Vangrevelinghe, Christoph Gaul, Thomas Radimerski, Anthony Letai, David M. Weinstock	2014	1
4	Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). Journal of Clinical Oncology ·Friedrich Hetzel, Martin Schüler, Jean‐Pascal Machiels, Dagmar Hess, Luis Paz‐Ares, Ahmad Awada, Roger von Moos, Neeltje Steeghs, Jordi Rodón, Mohammad Morshedi, Heike Richly, Samara Khorchid, Markus Joerger, Jesús Corral Jaime, María Alsina, Fabienne Baffert, David Demanse, Vincent Duval, S. Martellotti, Luc Dirix	2014	14
5	Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models Blood ·Sara C. Meyer, Matthew D. Keller, Priya Koppikar, Olga A. Guryanova, Maria Kleppe, Anna Sophia McKenney, William R. Sellers, Francesco Hofmann, Fabienne Baffert, Christoph Gaul, Thomas Radimerski, Ross L. Levine	2014	4
6	Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). Journal of Clinical Oncology ·Jordi Rodón, Martin Schüler, Jean‐Pascal Machiels, Dagmar Hess, Luis Paz‐Ares, Ahmad Awada, Roger von Moos, Neeltje Steeghs, Friedrich Hetzel, Mohammad Morshedi, Heike Richly, Samara Khorchid, Markus Joerger, Jesús Corral Jaime, María Alsina, Fabienne Baffert, David Demanse, Vincent Duval, S. Martellotti, Luc Dirix	2014	7
7	JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease Clinical Cancer Research ·Inger Juncker, Nicolas Ebel, Vincent Romanet, Olivia L. Hendricks, Rita Andraos, G. Daubercies, Pouteau Bertrand, Ernesta Dammassa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Baffert, Thomas Radimerski	2013	59
8	Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease Blood ·Fabienne Baffert, Inger Juncker, Nicolas Ebel, Olivia L. Hendricks, Rita Andraos, G. Daubercies, Vincent Romanet, Masato Murakami, Thomas Radimerski	2011	22
9	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Marc Gerspacher, Pascal Furet, Carole Pissot‐Soldermann, Christoph Gaul, Philipp Holzer, Eric Vangrevelinghe, Marc Lang, Dirk Erdmann, Thomas Radimerski, Catherine H. Régnier, Patrick Chêne, Alain De Pover, Francesco Hofmann, Fabienne Baffert, Thomas Buhl, Reiner Aichholz, Francesca Blasco, Carol Moor, Jörg Trappe, Peter Drueckes	2010	21
10	Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Carole Pissot‐Soldermann, Marc Gerspacher, Pascal Furet, Christoph Gaul, Philipp Holzer, Clive McCarthy, Thomas Radimerski, Catherine H. Régnier, Fabienne Baffert, Peter Drueckes, Gisele Tavares, Eric Vangrevelinghe, Francesca Blasco, Giorgio Ottaviani, Sung-wook Nam, Worku Birhanu Sefer, 俊行志賀	2010	33
11	Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics Cancer Research ·Anderson Materson Silva, Ivana Samaržija, Fabienne Baffert, Amanda Littlewood‐Evans, Christian Schnell, Andreas Theuer, Sven Christian, Anja M. Boos, Holger Hess‐Stumpp, John A. Foekens, Buddy Setyono-Han, Jeanette M. Wood, Nancy E. Hynes	2008	32
12	Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling American Journal of Physiology-Heart and Circulatory Physiology ·Fabienne Baffert, Tom Le, Barbara Sennino, Gavin Thurston, Calvin J. Kuo, Dana D. Hu‐Lowe, Donald M. McDonald	2005	277
13	Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules American Journal of Physiology-Heart and Circulatory Physiology ·Fabienne Baffert, Tom Le, Gavin Thurston, Donald M. McDonald	2005	118
14	Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting,during a critical developmental period Development ·Gavin Thurston, Quan Wang, Fabienne Baffert, John S. Rudge, Nicholas Papadopoulos, Erlino Østeroaard, Stanley J. Wiegand, George D. Yancopoulos, Donald M. McDonald	2005	86
15	Long-Term and Sustained COMP-Ang1 Induces Long-Lasting Vascular Enlargement and Enhanced Blood Flow Circulation Research ·Chung‐Hyun Cho, Kyung Eun Kim, Jonghoe Byun, Ifeyinwa Ekulide, Duk‐Kyung Kim, Peter Bałuk, Fabienne Baffert, Gyun Min Lee, Naoki Mochizuki, Jin Kim, Byeong Hwa Jeon, Donald M. McDonald, Gou Young Koh	2005	114
16	Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts American Journal Of Pathology ·Tetsuichiro Inai, Michael R. Mancuso, Hiroya Hashizume, Fabienne Baffert, Amy Haskell, Peter Bałuk, Dana D. Hu‐Lowe, David R. Shalinsky, Gavin Thurston, George D. Yancopoulos, Donald M. McDonald Hit paper breakdown →	2004	589
17	Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1-Induced Plasticity of Adult Blood Vessels Circulation Research ·Fabienne Baffert, Gavin Thurston, Isaac Aguilar, Tom Le, Rolf A. Brekken, Donald M. McDonald	2004	100
18	The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. PubMed ·Richard Béliveau, Denis Gingras, Erwin A. Kruger, Sylvie Lamy, Pierré Sirois, Yegor V. Tourleigh, Martin G. Sirois, Léone Tranqui, Fabienne Baffert, Édith Beaulieu, Violetta Dimitriadou, Marie-Claude Pépin, Frank Courjal, Isabelle Ricard, Patrick Poyet, Pierre Falardeau, William D. Figg, Éric Dupont	2002	54
19	Effects of prolonged exposure to hypoxia on morphological changes of endothelial cells plated on fibrin gel European Journal of Cell Biology ·Fabienne Baffert, Yves Usson, Léone Tranqui	2001	4

About Fabienne Baffert

Fabienne Baffert is a scholar working on Genetics, Internal Medicine, Oncology, Hematology and Critical Care and Intensive Care Medicine, having authored 19 papers that have together received 1.5k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Cytokine Signaling Pathways and Interactions (4 papers), Advanced Breast Cancer Therapies (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Lymphatic System and Diseases (2 papers), Cancer Treatment and Pharmacology (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). The work is most often cited by research in Cancer Research (341 citations), Genetics (177 citations), Oncology (434 citations), Molecular Biology (968 citations) and Ophthalmology (106 citations). Fabienne Baffert has collaborated with scholars based in Switzerland, United States and Spain. Frequent co-authors include Donald M. McDonald, Gavin Thurston, Dana D. Hu‐Lowe, Tom Le, George D. Yancopoulos, Peter Bałuk, Tetsuichiro Inai, David R. Shalinsky, Michael R. Mancuso and Hiroya Hashizume. Their work appears in journals such as Blood, Journal of Clinical Oncology, Bioorganic & Medicinal Chemistry Letters, Circulation Research and American Journal of Physiology-Heart and Circulatory Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact